A Phase I clinical trial of Foghorn’s FHD-286, which was placed on a partial hold in May after one death, is on a full hold now that multiple deaths may be attributed to differentiation syndrome.

The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.